GlassScriptPhysician profile
Christopher L Daniels
NPI 1952519670
$120,483.81
in general payments reported to CMS, 2019-2025
41 companies · $5,212 in 2025
The $5,212 reported for 2025 was more than what 83% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,538 · 2020: $2,600 · 2021: $5,670 · 2022: $66K · 2023: $23K · 2024: $14K · 2025: $5,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Long Term Medical Supply Or Device Loan: $12K · Food and Beverage: $7,418 · Travel and Lodging: $2,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,825.00 |
| Long Term Medical Supply Or Device Loan | $12,000.00 |
| Food and Beverage | $7,418.20 |
| Travel and Lodging | $2,987.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $84,714.25 | 2019-2024 | Xarelto |
| Angiodynamics, INC. | $12,559.73 | 2022-2024 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $5,085.85 | 2019-2025 | Aveir, Xience Skypoint, Confirm Rx |
| Bard Peripheral Vascular, INC. | $3,448.16 | 2020-2025 | Rotarexs 6 F X 135 Cm, Venovo, Lifestream |
| Cardiovascular Systems INC. | $3,198.64 | 2019-2023 | Diamondback Coronary |
| Medtronic, INC. | $2,728.53 | 2021-2025 | Azure Xt Dr Mri Surescan, Attain Performa Mri Surescan, Micra |
| Abiomed | $1,269.60 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $1,128.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,039.64 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Shockwave Medical, INC | $896.94 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $543.50 | 2020-2023 | Avvigo Guidance System, Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $472.25 | 2019-2025 | Lifevest |
| Amgen INC. | $426.88 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $416.63 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $408.13 | 2019-2025 |
Show all 39 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.